# Zephyrm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zephyrm

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.zephyrm.com
- Total disclosed funding: $29M
- Latest round: Series B (Apr 17, 2023)
- Investors on record: 7

## About

Established in 2018 and based in Beijing, China, Zephyrm is a biotech company that focuses on stem cell drug development and production. In May 2019, it established a GMP stem cell drug production plant in Zhongguancun Science and Technology Park in Beijing, and the stem cell drug production plant is equipped with complete cell culture and testing facilities. In September 2021, it received approval for a new drug clinical trial for stem cell drugs to treat meniscal injuries. In April 2023, it raised over CNY 200 million in series B funding led by new investor CCB Investment Funds Management.

The company's main business is stem cell drug development and production. Its stem cell drug products are mainly involved in meniscal injuries in the osteoarticular system, acute respiratory distress syndrome and pulmonary fibrosis-related diseases in the respiratory system, and early-onset ovarian insufficiency in the reproductive system.

The company will use the series B funding for phase I-II registration clinical studies, technology platform expansion, and construction of industrial-grade cell production bases for pluripotent stem cell drugs in various fields such as lung diseases, degenerative joint diseases, central nervous system diseases, and retinal congenital/degenerative diseases.

## Funding rounds

- Series B, Apr 17, 2023, $29M — CCB Investment Funds Management
- Series A, Apr 14, 2021 — Vulcan, CASH Capital, 3E Bioventures Capital, Shanxi Growth Enterprise Leading Fund, Ruihe Xingye Asset
- Angel, Dec 27, 2019 — Casstar Capital

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series A
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series A
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series A
- Shanxi Growth Enterprise Leading Fund (https://capitalatlas.ai/funds/shanxi-growth-enterprise-leading-fund) — Series A
- Ruihe Xingye Asset (https://capitalatlas.ai/funds/ruihe-xingye-asset) — Series A
- CCB Investment Funds Management (https://capitalatlas.ai/funds/ccb-investment-funds-management) — Series B